CHEMICON International, Inc. (SERO) And Cellumen, Inc. Announce An R & D Agreement To Commercialize A Systems Cell Biology Approach To Cytotoxicity Profiling In Drug Discovery
2/7/2006 12:41:12 PM
ATLANTA--(BUSINESS WIRE)--Feb. 7, 2006--Serologicals Corporation (NASDAQ: SERO) announced today that Chemicon International, Inc., its wholly-owned subsidiary, has entered into a research and development agreement with Cellumen, Inc., to commercialize a cytotoxicity profiling panel and services designed with Chemicon and Upstate's market-leading cellular assay reagents and Cellumen's system cell biology approach. Chemicon will focus on the development and production of the resulting assays and panels, while Cellumen will focus on their use in profiling services and knowledge generation. The companies will jointly market these solutions to the pharmaceutical industry.
comments powered by